Ind-Swift Labs - Ind-Swift Laboratories Share Price

163.034.41 (2.78%)

Closed
As On: 12 Jun, 2026, 04:06 PM IST
As On: 12 Jun, 2026, 03:55 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	161.80
High	164.00
Low	159.21
Prev Close	158.63
Volume	3,72,371
VWAP(₹)	162.25

Share Price	Value
Today/Current/Last	163.03162.60
Previous Day	158.63158.35

Ind-Swift Labs Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Ind-Swift Labs Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	178.43	170.50	167.32	142.70	22.48
Total Income Growth (%)	4.65	1.91	17.25	534.86	-9.96
Total Expenses	161.37	158.15	155.81	-61.01	23.44
Total Expenses Growth (%)	2.04	1.50	-355.38	-360.24	-2.18
EBIT	17.07	12.36	11.51	203.71	-0.97
EBIT Growth (%)	38.10	7.41	-94.35	-	-197.23
Profit after Tax (PAT)	9.54	7.99	8.77	222.27	0.01
PAT Growth (%)	19.37	-8.94	-96.05	0.36	-98.50
EBIT Margin (%)	9.56	7.25	6.88	142.76	-4.30
Net Profit Margin (%)	5.35	4.69	5.24	155.77	0.03
Basic EPS (₹)	1.17	1.00	1.28	32.96	0.00

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	177.06	168.30	162.58	149.16	15.22
Total Income Growth (%)	5.21	3.52	9.00	880.13	-2.77
Total Expenses	158.77	155.22	151.60	-50.23	10.47
Total Expenses Growth (%)	2.28	2.39	-401.81	-579.83	-29.85
EBIT	18.29	13.07	10.98	199.39	4.75
EBIT Growth (%)	39.91	19.08	-94.49	0.00	550.08
Profit after Tax (PAT)	10.74	8.76	8.12	218.09	4.64
PAT Growth (%)	22.67	7.85	-96.28	0.00	1,349.36
EBIT Margin (%)	10.33	7.77	6.75	133.68	31.21
Net Profit Margin (%)	6.07	5.20	4.99	146.21	30.47
Basic EPS (₹)	1.32	1.10	1.18	32.34	0.78

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	643.09	1,326.27	1,240.81	1,081.45	914.04
Total Revenue Growth (%)	-51.51	6.89	14.74	18.31	12.42
Total Expenses	608.50	1,131.10	1,127.64	1,068.92	896.03
Total Expenses Growth (%)	-46.20	0.31	5.49	19.29	7.59
Profit after Tax (PAT)	250.48	420.96	47.60	-2.15	-3.15
PAT Growth (%)	-40.50	784.44	-	-	-
Operating Profit Margin (%)	6.67	19.22	17.00	10.40	13.26
Net Profit Margin (%)	44.59	32.86	3.94	-0.20	-0.35
Basic EPS (₹)	37.25	71.24	8.10	-0.36	-0.53

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	630.92	1,272.63	1,185.24	1,029.81	879.71
Total Revenue Growth (%)	-50.42	7.37	15.09	17.06	11.66
Total Expenses	589.98	1,081.75	1,079.39	1,020.12	863.59
Total Expenses Growth (%)	-45.46	0.22	5.81	18.13	6.96
Profit after Tax (PAT)	256.09	418.39	42.47	-5.71	-4.40
PAT Growth (%)	-38.79	885.10	-	-	-
Operating Profit Margin (%)	7.97	19.71	17.18	10.64	13.58
Net Profit Margin (%)	46.59	34.08	3.68	-0.57	-0.51
Basic EPS (₹)	38.08	70.81	7.19	-0.97	-0.74

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 21.52% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	1,438.34	1,165.11	1,824.06	1,800.83	1,818.45
Total Assets Growth (%)	23.45	-36.13	1.29	-0.97	-2.76
Total Liabilities	251.17	233.67	1,142.13	1,199.97	1,215.03
Total Liabilities Growth (%)	7.49	-79.54	-4.82	-1.24	-1.17
Total Equity	1,172.96	931.44	681.93	600.86	603.42
Total Equity Growth (%)	25.93	36.59	13.49	-0.42	-5.81
Current Ratio (x)	3.92	2.99	3.14	3.22	3.00
Total Debt to Equity (x)	0.02	0.02	1.73	2.35	2.56
Contingent Liabilities	0.11	1.36	10.22	39.42	45.91

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	1,422.05	1,104.79	1,788.27	1,802.91	1,817.20
Total Assets Growth (%)	28.72	-38.22	-0.81	-0.79	-2.31
Total Liabilities	243.77	182.54	1,112.93	1,170.36	1,178.51
Total Liabilities Growth (%)	33.54	-83.60	-4.91	-0.69	-3.05
Total Equity	1,164.08	922.24	675.35	632.56	638.69
Total Equity Growth (%)	26.22	36.56	6.76	-0.96	-0.92
Current Ratio (x)	3.67	3.06	3.07	3.19	3.02
Total Debt to Equity (x)	0.02	0.01	1.73	2.16	2.33
Contingent Liabilities	0.11	1.36	13.95	39.42	45.91

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	-25.47	-163.12	194.62	150.27	134.95
Net Cash used in Investing Activities	-109.62	-104.32	-13.37	4.77	-10.17
Net Cash flow from Financing Activities	69.20	698.91	-185.66	-140.88	-123.75
Net Cash Flow	-65.89	431.93	-3.28	9.88	1.02
Closing Cash & Cash Equivalent	428.04	431.93	18.20	21.48	11.60
Closing Cash & Cash Equivalent Growth (%)	-0.90	2,273.25	-15.26	85.14	9.62
Total Debt/ CFO (x)	-1.04	-0.10	4.43	6.34	7.45

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	-39.15	-179.77	182.67	136.26	135.03
Net Cash used in Investing Activities	-109.67	-104.32	-13.69	2.76	-10.17
Net Cash flow from Financing Activities	74.22	699.86	-168.41	-139.59	-123.75
Net Cash Flow	-74.60	415.77	0.58	-0.57	1.11
Closing Cash & Cash Equivalent	413.01	425.73	9.96	9.38	9.95
Closing Cash & Cash Equivalent Growth (%)	-2.99	4,175.68	6.15	-5.75	12.59
Total Debt/ CFO (x)	-0.59	-0.05	4.67	6.93	7.38

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 72.68 cr for investing activities which is an YoY decrease of 33.7%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	21.32	45.19	9.54	-0.53	-0.80
Return on Capital Employed (%)	3.08	26.09	14.13	7.36	7.86
Return on Assets (%)	17.41	36.13	2.60	-0.11	-0.17
Interest Coverage Ratio (x)	21.24	5.86	2.85	2.50	2.05
Asset Turnover Ratio (x)	0.43	0.86	0.67	0.55	49.01
Price to Earnings (x)	2.31	1.38	6.94	-185.19	-136.99
Price to Book (x)	0.49	0.62	0.66	0.98	1.10
EV/EBITDA (x)	3.06	0.55	4.47	5.55	6.93
EBITDA Margin (%)	11.03	23.38	21.75	23.01	23.05

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	23.49	45.36	8.63	-1.30	-1.02
Return on Capital Employed (%)	3.63	26.11	13.76	7.06	7.60
Return on Assets (%)	18.00	37.87	2.37	-0.31	-0.24
Interest Coverage Ratio (x)	23.42	5.78	2.77	2.47	2.03
Asset Turnover Ratio (x)	0.44	0.85	0.64	0.55	0.47
Price to Earnings (x)	2.25	1.39	7.78	-69.93	-98.04
Price to Book (x)	0.53	0.63	0.67	0.91	1.01
EV/EBITDA (x)	2.95	0.55	4.60	5.64	6.96
EBITDA Margin (%)	12.43	24.05	22.16	23.90	23.77

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Ind-Swift Labs	34.18	1.02	2.99	4.33	2.47	-17.67	9.58	6.44	4.95	3.83	0.01	-0.28
Venus Remedies	23.37	3.62	15.48	19.39	12.03	11.28	17.43	13.35	76.89	2.44	0.00	0.00
NGL Fine Chem	39.21	5.72	14.61	17.15	8.82	21.81	13.54	9.60	77.90	1.84	0.33	2.50
Lincoln Pharma	14.50	1.68	11.60	14.96	9.87	9.66	17.38	13.09	43.88	5.25	0.01	0.04
Wanbury Ltd	14.50	16.19	51.50	27.78	7.37	9.07	11.09	5.09	9.32	1.11	2.92	6.64
Add More

Annual Ratios (%)

Choose from Peers

Themis Medicare
Kopran Ltd
Anuh Pharma
Kilitch Drug
Albert David

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Ind-Swift Labs Stock Performance	2.78	21.11	13.26	14.90	126.62	133.90	95.71
Venus Remedies Stock Performance	4.81	91.69	75.54	136.72	413.72	797.40	460.32
NGL Fine Chem Stock Performance	12.24	34.21	35.02	29.94	137.15	100.55	0.00
Lincoln Pharma Stock Performance	1.03	-4.50	4.60	2.17	5.05	44.16	94.32
Wanbury Ltd Stock Performance	7.27	6.19	6.29	1.70	-5.91	470.20	166.94
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	3,73,34,278	42.99 %	3.49
Pledge	0	0.00 %	0.00
FII	1,20,54,112	13.88 %	-0.44
DII	300	0.00 %	-0.68
MF	300	0.00 %	0.00
Others	3,74,47,868	43.12 %	-2.36

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	42.99	39.50	39.50	40.94
Pledge	0.00	0.00	0.00	0.00
FII	13.88	14.33	14.80	4.27
DII	0.00	0.68	0.68	0.91
Mutual Funds	0.00	0.00	0.00	0.00
Others	43.12	45.49	45.02	53.88

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Audited Results
May 22, 2026
General Meeting
-
Mar 30, 2026
Board Meeting
Quarterly Results
Jan 28, 2026

Board Meetings

Announced on	Meeting on
May 22, 2026	May 28, 2026
Audited Results
Jan 28, 2026	Jan 31, 2026
Quarterly Results
Nov 07, 2025	Nov 14, 2025
Quarterly Results
Aug 04, 2025	Aug 13, 2025
Quarterly Results
Aug 01, 2025	Aug 11, 2025
Audited Results

Dividends
Announced on Ex-Date Dividend%
May 26, 2011 Sep 20, 2011 10%
May 30, 2010 Sep 16, 2010 10%
Jun 30, 2009 Sep 17, 2009 10%
Jun 24, 2008 Sep 18, 2008 10%
Jul 30, 2007 Sep 21, 2007 10%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Mar 30, 2026 May 02, 2026
-
Sep 02, 2025 Sep 29, 2025
-
Jan 20, 2025 Feb 22, 2025
-
Aug 14, 2024 Sep 30, 2024
A.G.M.
Jun 28, 2024 Jul 22, 2024
-

Announced on	Ex-Date	Dividend%
May 26, 2011	Sep 20, 2011	10%
May 30, 2010	Sep 16, 2010	10%
Jun 30, 2009	Sep 17, 2009	10%
Jun 24, 2008	Sep 18, 2008	10%
Jul 30, 2007	Sep 21, 2007	10%

Announced on	Meeting on
Mar 30, 2026	May 02, 2026
-
Sep 02, 2025	Sep 29, 2025
-
Jan 20, 2025	Feb 22, 2025
-
Aug 14, 2024	Sep 30, 2024
A.G.M.
Jun 28, 2024	Jul 22, 2024
-

About Ind-Swift Labs

Ind-Swift Laboratories Ltd., incorporated in the year 1995, is a Small Cap company (having a market cap of Rs 1,415.70 Crore) operating in Pharmaceuticals sector.

Ind-Swift Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals and Sale of services for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 172.01 Crore, down 3.60 % from last quarter Total Income of Rs 178.43 Crore and up 20.54 % from last year same quarter Total Income of Rs 142.69 Crore. Company has reported net profit after tax of Rs 15.11 Crore in latest quarter.

The company’s top management includes Mr.Navrattan Munjal, Mr.Himanshu Jain, Mr.Rishav Mehta, Mr.Sahil Munjal, Ms.Neerja Chathley, Mr.Prabhat Khurana, Mr.Rajinder Kumar Gupta, Mr.Subodh Gupta, Mr.Gagan Aggarwal, Mr.Anil Ratanlal Agrawal, Mr.Pardeep Verma. Company has Rattan Kaur & Associates as its auditors. As on 31-03-2026, the company has a total of 8.68 Crore shares outstanding.

Ind-Swift Labs Share Price Today is Rs. 163.03. On previous day, the Ind-Swift Labs Share Price (NSE) closed at Rs. 158.63, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 42.99% of the stake in Ind-Swift Labs shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Ind-Swift Labs stocks was 13.88% as compared to 14.33% in Dec 2025 with decrease of 0.45%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.68% in Dec 2025 with decrease of 0.68%. Out of the total DII holdings in Ind-Swift Labs shares 0.0% was held by mutual funds. The rest including public held is 43.13%. Ind-Swift Labs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Ind-Swift Labs Dividend: Ever since 1995, Ind-Swift Labs dividends has been paid out around 11 times. As on 12 Jun, 2026, 04:06 PM IST, The overall dividend yield for Ind-Swift Labs stands at 0.0%. The last dividend paid was on September 20, 2011 (Rs. 1.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 4.77.

Ind-Swift Labs Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 172.01 Cr. of sales and 3.6% of quarterly net loss, there have been multiple ups and downs in the Ind-Swift Labs stock prices in the past few weeks. For example, Ind-Swift Labs stock price on 5th of June 2026 was around Rs. 158.0. Ind-Swift Labs share price now stands at an average of Rs. 163.03. Judging by last week's performance, stock is in up trend.

Ind-Swift Labs has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Ind-Swift Labs share.

Historical Prices and Performance:
Ind-Swift Labs, incorporated in 1995 is a Small Cap company (with a market cap of Rs. 1415.7) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Ind-Swift Labs stock was 2.99%, 21.32%, 45.19%, 9.54% and -0.53% respectively.
The Ind-Swift Labs share gave a 3 year return of 133.73% as compared to Nifty 50 which gave a return of 26.99%.
Ind-Swift Labs announced 10.0% final dividend on September 20, 2011.

Key Metrics:
PE Ratio of Ind-Swift Labs is 33.26
Prices/Sales Ratio of Ind-Swift Labs is 1.78
Price/Book Ratio of Ind-Swift Labs is 1.0

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Ind-Swift Labs, major competitors and peers include Venus Remedies, NGL Fine Chem, Lincoln Pharma and Wanbury Ltd. As of Dec 2025, the dividend yield of Ind-Swift Labs stands at 0.0% while Venus Remedies, NGL Fine Chem, Lincoln Pharma and Wanbury Ltd stand at 0.56%, 0.06%, 0.0% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 33.26 and 1.0 respectively.

Leadership of Ind-Swift Labs :
Pardeep Verma is Vice President (Corp. Affairs) & Co. Secretary
Gagan Aggarwal is Chief Financial Officer
Varun Chhabra is Senior Vice President
Akashdeep Sharma is Vice President - HR
Lalit Goyal is General Manager - Accounts
Anil Ratanlal Agrawal is Chief Operating Officer
Ravi Kumar Bhardwaj is Vice President - Operations
Pratik Kumar is Vice President
Vivek Mishra is Vice President
Viren Ramkrishna Nagar is Vice President
Navrattan Munjal is Chairman & Managing Director
Himanshu Jain is Joint Managing Director
Rishav Mehta is Executive Director
Sahil Munjal is Executive Director
Rajinder Kumar Gupta is Independent Director
Prabhat Khurana is Independent Director
Subodh Gupta is Independent Director
Neerja Chathley is Independent Woman Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

SCO 850, Shivalik Enclave,NAC, Manimajra,Chandigarh, Chandigarh - 160101

Contact

investor@indswiftlabs.com

http://www.indswiftlabs.com

PE Ratio(x)	34.18
EPS - TTM(₹)	4.77
MCap(₹ Cr.)	1,415.70
MCap Rank	84
PB Ratio(x)	1.02
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	173.25
52W Low(₹)	87.15
MCap/Sales	1.78
Beta(1 Month)	0.40
BV/Share(₹)	159.38

PE Ratio(x)	34.09
EPS - TTM(₹)	4.77
MCap(₹ Cr.)	1,411.96
MCap Rank	83
PB Ratio(x)	0.99
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	173.50
52W Low(₹)	87.00
MCap/Sales	1.78
Beta(1 Month)	0.09
BV/Share(₹)	159.38

1 Day	2.78%
1 Month	18.34%
3 Months	13.63%
1 Year	47.86%
3 Years	133.73%
5 Years	37.81%

1 Day	2.68%
1 Month	17.91%
3 Months	13.55%
1 Year	48.02%
3 Years	134.33%
5 Years	35.9%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Ind-Swift Labs - Ind-Swift Laboratories Share Price

Key Metrics

Ind-Swift Labs share price insights

Ind-Swift Labs Share Price Returns

Ind-Swift Labs Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Ind-Swift Labs Top Searches

Corporate Actions

About Ind-Swift Labs

Executive Leadership

Auditors

FAQs about Ind-Swift Labs share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News